Answers are grounded in this paper and cite their sources.
Comprehensive review reveals advancing nanotechnology, AI, and fluid biomarkers for early Alzheimer's disease detection, highlighting potential for personalized clinical management.
Background Memory decline, β-amyloid plaque buildup, & neural tangles are the hallmarks of Alzheimer's, a degenerative neurologic condition. The scarcity of efficacious treatments underscores the necessity of early-stage detection approaches. Objective With a focus on inorganic metallic-based diagnostic instruments, biosensor technologies, AI, and precision medicine techniques, this study attempts to provide an overview of current developments in biomarker-based detection of Alzheimer's disease. Methods A thorough evaluation of the existing research on neuroimaging biomarkers was conducted on neuroimaging biomarkers, circulating biomarkers, CSF biological markers, nanotechnology-driven biosensors, inorganic nanoparticles of metal, and AI-assisted diagnostic models. To comprehend their function in early identification and illness monitoring, studies concentrating on molecular, inflammatory, and multi-omics biomarkers were included. Result In AD, indicators obtained through MRI, PET scans, as well as the analysis of CSF are essential for identifying aberrant buildup of protein as well as degeneration of neurons. Emerging non-invasive biomarkers identified in plasma, saliva, urine, and breath have shown potential for early-stage diagnosis. Inorganic metals and metal-based nanomaterials, including gold, silver, iron oxide, copper, zinc, and selenium nanoparticles, enhance biosensor sensitivity and facilitate ultrasensitive detection of β-amyloid and tau proteins. AI approaches such as machine learning and deep learning improve diagnostic accuracy through integration of neuroimaging and multi-omics data. Additionally, inflammatory biomarkers and circulating microRNAs contribute to disease stratification and prediction. Conclusion This study critically reviews existing and developing biomarkers for Alzheimer's disease, with a focus on inorganic metallic nanostructures, biosensors, artificial intelligence, and precision medicine. It also highlights current translational challenges, identifies existing research gaps, and discusses future strategies, such as green nanotechnology and sustainable diagnostic platforms, to help develop clinically applicable and personalized Alzheimer's disease management approaches.
No takes yet. Share an insight, caveat, or question.
Mittal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: